Post Translational Medicines Inc

Post Translational Medicines Inc is a Singapore-based biotechnology company focused on drug discovery by targeting the previously inaccessible Dark Proteome, aiming to develop innovative therapeutic solutions for difficult diseases. Founded in 2025, Post Translational Medicines Inc specializes in drug discovery, particularly through their Surveyor™ Platform, which decodes proteoforms for novel treatments. The company has completed 1 deal as of July 31, 2025. The founder's history is not specified in the available data.

Post Translational Medicines specializes in drug discovery through the innovative exploration and targeting of the Dark Proteome, which consists of previously undruggable therapeutic targets. Their flagship offering, the Surveyor™ Platform, systematically decodes the complex landscape of proteoforms, enabling novel in cellulo drug discovery. This technology serves pharmaceutical companies and research institutions seeking new therapeutic pathways for historically difficult-to-treat diseases. The company's solutions are applicable in North America, Europe, and select regions in Asia, where biopharmaceutical research is prioritized.

By illuminating the Dark Proteome, Post Translational Medicines aims to redefine medicine and improve treatment options for previously overlooked conditions. Post Translational Medicines generates revenue through partnerships and collaborations with leading pharmaceutical and biotechnology firms, focusing on B2B transactions. These engagements typically involve licensing their Surveyor™ Platform technology and research agreements targeting specific proteoforms. The pricing structure aligns with the advanced nature of their offerings, reflecting their expertise in this niche market, enabling them to capitalize on the demand for innovative therapeutic solutions within the biopharmaceutical industry.

Post Translational Medicines plans to utilize the recent seed funding raised in July 2025 from SOSV to enhance their Surveyor™ Platform and develop new products aimed at addressing challenging therapeutic targets. The company is also targeting expansion into additional markets, with specific plans for North America and Europe by 2026 to increase their global footprint and leverage the growing demand for biopharmaceutical research.